These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 19125557)

  • 1. The future of Medicare Part D drug plans--results from a roundtable discussion.
    Balfour DC; Evans S; Januska J; Lee HY; Lewis SJ; Nolan SR; Noga M; Stemple C; Thapar K
    J Manag Care Pharm; 2009; 15(1 Suppl A):18-21. PubMed ID: 19125557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Medicare Part D-a roundtable discussion of current issues and trends.
    Balfour DC; Evans S; Januska J; Lee HY; Lewis SJ; Nolan SR; Noga M; Stemple C; Thapar K
    J Manag Care Pharm; 2009; 15(1 Suppl A):3-9. PubMed ID: 19125555
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Medicare program; Medicare prescription drug benefit. Final rule.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2005 Jan; 70(18):4193-585. PubMed ID: 15678603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mind the Gap: Why Closing the Doughnut Hole Is Insufficient for Increasing Medicare Beneficiary Access to Oral Chemotherapy.
    Dusetzina SB; Keating NL
    J Clin Oncol; 2016 Feb; 34(4):375-80. PubMed ID: 26644524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medicare part D: selected issues for plan sponsors, pharmacists, and beneficiaries in 2008.
    Depue R; Stubbings J
    J Manag Care Pharm; 2008; 14(1):50-60. PubMed ID: 18240882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medicare Part D: selected issues for pharmacists and beneficiaries in 2007.
    Kilian J; Stubbings J
    J Manag Care Pharm; 2007; 13(1):59-65. PubMed ID: 17269838
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adverse selection in the Medicare prescription drug program.
    Riley GF; Levy JM; Montgomery MA
    Health Aff (Millwood); 2009; 28(6):1826-37. PubMed ID: 19887424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Falling into the doughnut hole: drug spending among beneficiaries with end-stage renal disease under Medicare Part D plans.
    Patel UD; Davis MM
    J Am Soc Nephrol; 2006 Sep; 17(9):2546-53. PubMed ID: 16855016
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in the prescription drug plans delivering the Medicare Part D prescription drug benefit.
    Brill JV
    Am J Health Syst Pharm; 2007 Aug; 64(15 Suppl 10):S3-6; quiz S21-S23. PubMed ID: 17646551
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Medicare program; Medicare prescription drug discount card. Interim final rule with comment period.
    Centers for Medicare & Medicaid Services (CMS), HHS
    Fed Regist; 2003 Dec; 68(240):69839-927. PubMed ID: 14674398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Should drug prices be negotiated under part D of Medicare? And if so, how?
    Frank RG; Newhouse JP
    Health Aff (Millwood); 2008; 27(1):33-43. PubMed ID: 18180478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medicare part D: ongoing challenges for doctors and patients.
    Jacobson G; Anderson G
    Annu Rev Med; 2010; 61():469-76. PubMed ID: 20059349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Medicare Part D: successes and continuing challenges. Impact of Medicare Part D on Massachusetts health programs and beneficiaries.
    Thomas CP; Sussman J; ;
    Issue Brief (Mass Health Policy Forum); 2007 May; (32):1-32. PubMed ID: 17546802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of statin adherence among beneficiaries in MA-PD plans versus PDPs.
    Jung K; McBean AM; Kim JA
    J Manag Care Pharm; 2012 Mar; 18(2):106-15. PubMed ID: 22380470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between dispensing channel and medication adherence among medicare beneficiaries taking medications to treat diabetes, high blood pressure, or high blood cholesterol.
    Iyengar RN; Balagere DS; Henderson RR; LeFrancois AL; Rabbitt RM; Frazee SG
    J Manag Care Spec Pharm; 2014 Aug; 20(8):851-61. PubMed ID: 25062079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
    Goedken AM; Urmie JM; Farris KB; Doucette WR
    Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Minimizing out-of-pocket prescription drug costs for Medicare beneficiaries: not just 'a drop in the bucket'.
    Patel RA; Vo KA; Chu T; Wang K; Lu S; Woelfel JA; Carr-Lopez SM; Galal SM
    J Am Pharm Assoc (2003); 2014; 54(6):604-9. PubMed ID: 25379981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Medicare Prescription Drug Plan Enrollees Report Less Positive Experiences Than Their Medicare Advantage Counterparts.
    Elliott MN; Landon BE; Zaslavsky AM; Edwards C; Orr N; Beckett MK; Mallett J; Cleary PD
    Health Aff (Millwood); 2016 Mar; 35(3):456-63. PubMed ID: 26953300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimating Medicare Part D's impact on medication access among dually eligible beneficiaries with mental disorders.
    Donohue JM; Frank RG
    Psychiatr Serv; 2007 Oct; 58(10):1285-91. PubMed ID: 17914004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improving Comprehensive Medication Review Acceptance by Using a Standardized Recruitment Script: A Randomized Control Trial.
    Miguel A; Hall A; Liu W; Garrett J; Ballew A; Yang TH; Segal R
    J Manag Care Spec Pharm; 2017 Jan; 23(1):13-21. PubMed ID: 28025924
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.